Table 2.
Characteristics of the psychiatry-liaison team consultations received by patients on the post-COVID-19 unit
| Variable | Count | |
|---|---|---|
| Mean ± Standard deviation | ||
| Day to psychiatry consult | 13 ± 21.51 | |
| Frequency (percentage) | ||
| Reason for a psychiatry consult | Low mood | 13 (25%) |
| Suicidality | 4 (7.7%) | |
| Anxiety/Panic attacks | 16 (30.8%) | |
| Agitation/Delirium | 19 (36.5%) | |
| Psychiatric symptoms present on assessment | Depressive symptoms | 26 (50%) |
| Suicidality | 20 (38.5%) | |
| Anxiety symptoms | 35 (67.3%) | |
| Panic symptoms | 11 (21.2%) | |
| Somatic symptoms | 2 (3.8%) | |
| Drug-related symptoms | 5 (9.6%) | |
| Delirium-related symptoms | 16 (30.8%) | |
| Trauma-related symptoms | 2 (3.8%) | |
| DSM-5 diagnosis as per the consulting team | Major depressive episode | 8 (15.4%) |
| Other mood disorder | 6 (11.5%) | |
| Adjustment disorder | 2 (3.8%) | |
| Panic attack/disorder | 3 (5.8%) | |
| Generalized anxiety disorder | 1 (1.9%) | |
| Other anxiety disorder | 8 (15.4%) | |
| Delirium | 16 (30.8%) | |
| Drug intoxication/withdrawal | 7 (13.5%) | |
| Serotonin syndrome | 2 (3.8%) | |
| Normal reaction to stress | 1 (1.9%) | |
| Pharmacological management | Selective serotonin reuptake inhibitor | 8 (15.4%) |
| Atypical antidepressant | 5 (9.6%) | |
| Tricyclic antidepressant | 1 (1.9%) | |
| 1st generation antipsychotic | 5 (9.6%) | |
| 2nd generation antipsychotic | 19 (36.5%) | |
| Benzodiazepine | 4 (7.7%) | |
| Cyproheptadine | 2 (3.8%) | |
| Lithium/mood stabilizer | 2 (3.8%) | |
| Melatonin | 2 (3.8%) | |
| Stimulant | 1 (1.9%) | |
| None | 5 (9.6%) | |
| Non-pharmacological management | Management of delirium | 16 (30.8%) |
| Referral to therapy | 7 (13.5%) | |
| Referral to social services | 1 (1.9%) | |
| Suicide precautions | 4 (7.7%) | |
| None | 24 (64.2%) | |
| Past psychiatric history | 24 (46.2%) | |
| Previous psychotropic medications | 19 (36.5%) | |
| Psychiatric family history | 11 (21.2%) | |